Literature DB >> 26376929

Proteins Selected in Leishmania (Viannia) braziliensis by an Immunoproteomic Approach with Potential Serodiagnosis Applications for Tegumentary Leishmaniasis.

Mariana C Duarte1, Daniel C Pimenta2, Daniel Menezes-Souza3, Rubens D M Magalhães4, João L C P Diniz5, Lourena E Costa5, Miguel A Chávez-Fumagalli5, Paula S Lage5, Daniela C Bartholomeu6, Maria Julia M Alves7, Ana Paula Fernandes8, Manuel Soto9, Carlos A P Tavares4, Denise U Gonçalves5, Manoel O C Rocha5, Eduardo A F Coelho10.   

Abstract

The serodiagnosis of human tegumentary leishmaniasis (TL) presents some problems, such as the low level of antileishmanial antibodies found in most of the patients, as well as the cross-reactivity in subjects infected by other trypanosomatids. In the present study, an immunoproteomic approach was performed aimed at identification of antigens in total extracts of stationary-phase promastigote and amastigote-like forms of Leishmania (Viannia) braziliensis using sera from TL patients. With the purpose of reducing the cross-reactivity of the identified proteins, spots recognized by sera from TL patients, as well as those recognized by antibodies present in sera from noninfected patients living in areas where TL is endemic and sera from Chagas disease patients, were discarded. Two Leishmania hypothetical proteins and 18 proteins with known functions were identified as antigenic. The study was extended with some of them to validate the results of the immunoscreening. The coding regions of five of the characterized antigens (enolase, tryparedoxin peroxidase, eukaryotic initiation factor 5a, β-tubulin, and one of the hypothetical proteins) were cloned in a prokaryotic expression vector, and the corresponding recombinant proteins were purified and evaluated for the serodiagnosis of TL. The antigens presented sensitivity and specificity values ranging from 95.4 to 100% and 82.5 to 100%, respectively. As a comparative antigen, a preparation of Leishmania extract showed sensitivity and specificity values of 65.1 and 57.5%, respectively. The present study has enabled the identification of proteins able to be employed for the serodiagnosis of TL.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26376929      PMCID: PMC4622107          DOI: 10.1128/CVI.00465-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  50 in total

1.  Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry.

Authors:  T S Lewis; J B Hunt; L D Aveline; K R Jonscher; D F Louie; J M Yeh; T S Nahreini; K A Resing; N G Ahn
Journal:  Mol Cell       Date:  2000-12       Impact factor: 17.970

2.  Characterization of novel Leishmania infantum recombinant proteins encoded by genes from five families with distinct capacities for serodiagnosis of canine and human visceral leishmaniasis.

Authors:  Geraldo G S Oliveira; Franklin B Magalhães; Márcia C A Teixeira; Andrea M Pereira; Cristiane G M Pinheiro; Lenita R Santos; Marília B Nascimento; Cheila N G Bedor; Alessandra L Albuquerque; Washington L C dos-Santos; Yara M Gomes; Edson D Moreira; Maria E F Brito; Lain C Pontes de Carvalho; Osvaldo P de Melo Neto
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

Review 3.  Diagnosis of cutaneous leishmaniasis.

Authors:  Francisco Vega-López
Journal:  Curr Opin Infect Dis       Date:  2003-04       Impact factor: 4.915

4.  Identification of potentially diagnostic Leishmania braziliensis antigens in human cutaneous leishmaniasis by immunoblot analysis.

Authors:  M E Brito; M G Mendonça; Y M Gomes; M L Jardim; F G Abath
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

5.  Linear B-cell epitope mapping of MAPK3 and MAPK4 from Leishmania braziliensis: implications for the serodiagnosis of human and canine leishmaniasis.

Authors:  Daniel Menezes-Souza; Tiago Antônio de Oliveira Mendes; Ana Carolina de Araújo Leão; Matheus de Souza Gomes; Ricardo Toshio Fujiwara; Daniella Castanheira Bartholomeu
Journal:  Appl Microbiol Biotechnol       Date:  2014-10-31       Impact factor: 4.813

Review 6.  Cutaneous leishmaniasis.

Authors:  Richard Reithinger; Jean-Claude Dujardin; Hechmi Louzir; Claude Pirmez; Bruce Alexander; Simon Brooker
Journal:  Lancet Infect Dis       Date:  2007-09       Impact factor: 25.071

7.  Cross-reactivity studies and differential serodiagnosis of human infections caused by Trypanosoma cruzi and Leishmania spp; use of immunoblotting and ELISA with a purified antigen (Ag163B6).

Authors:  E L Malchiodi; M G Chiaramonte; N J Taranto; N W Zwirner; R A Margni
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

8.  Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production.

Authors:  Lúcio Roberto Castellano; Dalmo Correia Filho; Laurent Argiro; Helia Dessein; Aluízio Prata; Alain Dessein; Virmondes Rodrigues
Journal:  Hum Immunol       Date:  2009-01-20       Impact factor: 2.850

9.  Molecular diagnosis of Old World leishmaniasis: real-time PCR based on tryparedoxin peroxidase gene for the detection and identification of Leishmania spp.

Authors:  Sharifeh Khosravi; Saied Hossein Hejazi; Mortaza Hashemzadeh; Gilda Eslami; Hossein Yousofi Darani
Journal:  J Vector Borne Dis       Date:  2012-03       Impact factor: 1.688

10.  Non-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: superior performance to conventional biopsy with histopathology.

Authors:  Andrea K Boggild; Braulio Mark Valencia; Nicolas Veland; Ana Pilar Ramos; Flor Calderon; Jorge Arevalo; Donald E Low; Alejandro Llanos-Cuentas
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

View more
  13 in total

1.  Evaluation of a hypothetical protein for serodiagnosis and as a potential marker for post-treatment serological evaluation of tegumentary leishmaniasis patients.

Authors:  Mariana Pedrosa Lima; Lourena Emanuele Costa; Mariana Costa Duarte; Daniel Menezes-Souza; Beatriz Cristina Silveira Salles; Thaís Teodoro de Oliveira Santos; Fernanda Fonseca Ramos; Miguel Angel Chávez-Fumagalli; Amanda Christine Silva Kursancew; Roberta Passamani Ambrósio; Bruno Mendes Roatt; Ricardo Andrez Machado-de-Ávila; Denise Utsch Gonçalves; Eduardo Antonio Ferraz Coelho
Journal:  Parasitol Res       Date:  2017-02-01       Impact factor: 2.289

2.  Development of an immunogen containing CD4+/CD8+ T-cell epitopes for the prophylaxis of tegumentary leishmaniasis.

Authors:  Isabela de Andrade Ferraz; Ana Maria Ravena Severino Carvalho; Rory Cristiane Fortes de Brito; Bruno Mendes Roatt; Vívian Tamietti Martins; Daniela Pagliara Lage; Luiza Dos Reis Cruz; Fernanda Alvarenga Cardoso Medeiros; Denise Utsch Gonçalves; Manoel Otávio da Costa Rocha; Eduardo Antonio Ferraz Coelho; Tiago Antônio de Oliveira Mendes; Mariana Costa Duarte; Daniel Menezes-Souza
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-27       Impact factor: 5.560

3.  Antileishmanial activity of a naphthoquinone derivate against promastigote and amastigote stages of Leishmania infantum and Leishmania amazonensis and its mechanism of action against L. amazonensis species.

Authors:  Débora Vasconcelos Costa Mendonça; Daniela Pagliara Lage; Stephane Lima Calixto; Flaviano Melo Ottoni; Grasiele de Sousa Vieira Tavares; Fernanda Ludolf; Miguel Angel Chávez-Fumagalli; Mônica Santos Schneider; Mariana Costa Duarte; Carlos Alberto Pereira Tavares; Ricardo José Alves; Elaine Soares Coimbra; Eduardo Antonio Ferraz Coelho
Journal:  Parasitol Res       Date:  2017-12-16       Impact factor: 2.289

Review 4.  Understanding Leishmania parasites through proteomics and implications for the clinic.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Proteomics       Date:  2018-05-02       Impact factor: 3.940

5.  Identification of Immunoreactive Leishmania infantum Protein Antigens to Asymptomatic Dog Sera through Combined Immunoproteomics and Bioinformatics Analysis.

Authors:  Maria Agallou; Evita Athanasiou; Martina Samiotaki; George Panayotou; Evdokia Karagouni
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

6.  Complete Molecular and Immunoprotective Characterization of Babesia microti Enolase.

Authors:  Xiangye Liu; Chen Zheng; Xiaoge Gao; Jiaxu Chen; Kuiyang Zheng
Journal:  Front Microbiol       Date:  2017-04-11       Impact factor: 5.640

7.  Analysis of the Antigenic and Prophylactic Properties of the Leishmania Translation Initiation Factors eIF2 and eIF2B in Natural and Experimental Leishmaniasis.

Authors:  Esther Garde; Laura Ramírez; Laura Corvo; José C Solana; M Elena Martín; Víctor M González; Carlos Gómez-Nieto; Aldina Barral; Manoel Barral-Netto; José M Requena; Salvador Iborra; Manuel Soto
Journal:  Front Cell Infect Microbiol       Date:  2018-04-05       Impact factor: 5.293

8.  New antigens for the serological diagnosis of human visceral leishmaniasis identified by immunogenomic screening.

Authors:  Ana Maria Ravena Severino Carvalho; Tiago Antônio de Oliveira Mendes; Eduardo Antonio Ferraz Coelho; Mariana Costa Duarte; Daniel Menezes-Souza
Journal:  PLoS One       Date:  2018-12-20       Impact factor: 3.240

9.  Diagnostic accuracy of Enzyme-Linked Immunosorbent Assays to detect anti-Leishmania antibodies in patients with American Tegumentary Leishmaniasis: a systematic review.

Authors:  Andernice Dos Santos Zanetti; Camila Massae Sato; Fabiana Gulin Longhi; Silvana Margarida Benevides Ferreira; Omar Ariel Espinosa
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2019-08-19       Impact factor: 1.846

10.  Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis.

Authors:  Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Bethina T Steiner; Grasiele S V Tavares; Vívian T Martins; Amanda S Machado; João A Oliveira-da-Silva; Thaís T O Santos; Camila S Freitas; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Maria V Humbert; Myron Christodoulides; Eduardo A F Coelho
Journal:  Vaccines (Basel)       Date:  2020-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.